Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.30 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034026 | 0.87 | MAPK7 (0.42) | KDRMAPK7MAPK14DCLK1DYRK3 | |
| SCHEMBL14286148 | 0.85 | MAPK1 (0.42) | — | |
| SCHEMBL5037077 | 0.85 | ALDH1A1 (0.36) | HCAR1CHRM4PIK3C3 | |
| SCHEMBL5784221 | 0.81 | HCAR1 (0.39) | HCAR1OPRD1OPRM1CCKBR | |
| SCHEMBL14286139 | 0.80 | ROCK2 (0.40) | MAPK7MAPK14ROCK2LYNGSK3A | |
| SCHEMBL5033986 | 0.80 | NOTUM (0.36) | NOTUMHCAR1TTRMAPK7MAPK14 | |
| SCHEMBL5037079 | 0.80 | KCNN4 (0.40) | NOTUM | |
| SCHEMBL14278786 | 0.79 | HCAR1 (0.38) | NOTUMHCAR1MDM2CHRM4HSP90AA1 | |
| SCHEMBL14278719 | 0.77 | OPRD1 (0.37) | OPRD1OPRM1CCKBRDHODH | |
| SCHEMBL14278772 | 0.77 | MAPK1 (0.49) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1660487-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | VERTEX PHARMACEUTICALS INCORPORATED | 2005-05-12 | — | — | US | disclosed |
| WO-2005016920-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | MET, PRKCH, DMPK | NOTUM 1441/4885HCAR1 4015/4885OPRD1 3515/4885 |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | MET, DMPK, CDK4 | NOTUM 1881/4885HCAR1 4132/4885OPRD1 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.